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ABSTRACT: 
Cardiovascular disease (CVD) ranks among the most common health-related and economic 
issues worldwide. Dietary factors are important contributors to cardiovascular risk, either 
directly, or through their effects on other cardiovascular risk factors including hypertension, 
dyslipidemia and diabetes mellitus. Nutraceuticals are natural nutritional compounds, which 
have been shown to be efficacious in preventative medicine or in the treatment of disease. 
Several foods and dietary supplements have been shown to protect against the development of 
cardiovascular disease. The aim of this review is to present an update on the most recent 
evidence relating to the use of nutraceuticals in the context of the prevention and treatment of 
cardiovascular disease.  
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INTRODUCTION 
Cardiovascular disease (CVD) is common, indeed the majority of adults above sixty years of 
age will experience some manifestation of CVD. Based on data from 2012 and 2013, it has 
been estimated that CVD is responsible for 17.3 million deaths annually worldwide (1). 
Morbidity is also high, and in Europe, 200 billion Euros of healthcare expenditure is 
attributable to CVD (2). Risk factors for CVD can be categorized as modifiable and non-
modifiable. Modifiable risk factors include obesity, hypertension, hyperlipidemia, diabetes 
mellitus, metabolic syndrome and lifestyle risk factors such as unhealthy diet, smoking and 
physical inactivity. Dietary factors are also important contributors to cardiovascular risk, 
either directly, or through their effects on other risk factors including hypertension, 
dyslipidemia and diabetes mellitus. (3). Reduction of risk factors in the population, especially 
blood pressure reduction and lipid-lowering can have important impacts upon mortality from 
CVD (4). 
Protective effects against CVD have been demonstrated for several foods and dietary 
supplements (5) thus presenting new possibilities for population-level reduction of CVD risk. 
Evidence suggests that this approach is very promising. For example, in the PREDIMED 
observational study, participants in the highest quintile of polyphenol consumption had a 
relative risk of cardiovascular disease of 54% compared to those in the lowest quintile (6). 
The aim of this review is to present an update on the most recent evidence relating to the use 
of nutraceuticals in the context of the prevention and treatment of cardiovascular disease. 
Unfortunately, few studies have measured the associations between nutraceutical 
consumptions and ‘hard’ outcomes such as mortality. Large randomized controlled trials are 
particularly rare, and thus there is a paucity of evidence in this area. Thus, our discussion will 
be largely focused on the effects of nutraceuticals on well-characterized risk factors for CVD. 
 
NUTRACEUTICALS 
The term ‘nutraceuticals’ was introduced by Stephen De Felice, founder and chairman of the 
Foundation for Innovation in Medicine, in 1989. A nutraceutical is defined as a ‘food, or parts 
of a food, that provide medical or health benefits, including the prevention and treatment of 
disease’ (7). The definition encompasses medicinal products made from natural ingredients. 
Several classes of nutraceuticals have been proposed to have potential benefits in the 
treatment of CVD and the ones with the strongest evidence are briefly summarized below.  
 
Sterols/stanols  
Plant sterols/stanols are phytosterols, and have been identified in a range of plant products 
including various fruits and vegetables, cereals, seeds and nuts. Their biological activity 
results from their molecular structural similarity to cholesterol (8).  
 
Polyphenols  
Polyphenols are phytochemicals with widespread distribution in foods of plant origin. They 
are found in fruits, vegetables, cereal and legumes. Additionally, they are found in beverages 
produced from plant products such as tea, coffee, wine and cocoa. Polyphenols are 
structurally diverse, and over 8000 have been identified. These include flavonoids, phenolic 
acids, stilbenes and lignans (9). Polyphenols found in grapes and grape derivatives, cocoa and 
tea are of interest in the prevention of cardiovascular disease. Phenolic compounds are found 
in grapes and these include anthocyanins, flavanols, flavonols, stilbenes and phenolic acids 
(10). Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is the most extensively studied grape-
derived stilbene contained mainly in grapes. However, resveratrol is common to a variety of 
species including cranberries, blueberries, peanuts, and Japanese knotweed (11).  
Derivatives of cocoa beans (Theobroma cacao) are widely consumed in cocoa and chocolate 
(12). A variety of polyphenols have been identified in cocoa and its derivative. These include 
catechins, flavonol glycosides, anthocyanins and procyanidins (13). Cocoa-containing foods 
provide a higher content of flavonoids per serving than other beverages such as red wine and 
tea (14). 
The very widespread and frequent consumption of tea makes investigation of its nutraceutical 
propertied essentials. Polyphenols found in tea include catechins, theaflavins, tannins, and 
flavonoids. The degree of fermentation of tea leaves influences the chemical composition. 
Green tea, which is minimally fermented, contains more catechins such as epigallocatechin 
gallate, epicatechin-3-gallate, epigallocatechin and epicatechin (15) whereas the more 
extensively fermented black tea is rich in flavins and thearubigins (16). 
 
Spirulina 
Spirulina is a blue-green microalga (Cyanobacterium). Spirulina is a rich source of protein, 
vitamins, minerals, carotenoids, and phycocyanins and has a very long history of use as a 
human foodstuff with no apparent concerns over safety (17,18). 
Table 1 summarizes the methodology and main findings from each study described in the 
paper.  
 
DYSLIPIDEMIA 
Dyslipidemia is an umbrella term for a variety of lipid abnormalities, which increase the risk 
of cardiovascular disease. Reduction of total cholesterol and low-density lipoprotein-
cholesterol (LDL-C) is effective in the primary and secondary prevention of CVD events (19). 
In particular, low LDL-C levels are associated with lower rates of major coronary events (20). 
Thus nutraceuticals with the potential to modify the plasma lipid profile have the potential to 
reduce the burden of CVD (21). Evidence related to the lipid-modifying effects of 
nutraceuticals is summarized below. 
 
Sterols/stanols 
Consumption of plant sterols/stanols has been shown to be associated with lower circulating 
concentrations of total cholesterol (TC) in humans (22,23). Their effect is predominantly 
LDL-C reduction with little or no effect on high-density lipoprotein cholesterol (HDL-C) or 
triglycerides (24). The mechanism by which sterols/stanols reduce LDL-C is associated with a 
reduction in the intestinal absorption of cholesterol, the upregulation of hepatic LDL receptors 
(and consequent increased hepatic cholesterol uptake) and reduced production of endogenous 
cholesterol (25). 
Circulating LDL-C concentrations are inversely correlated with the extent of sterol/stanol 
consumption. The reduction in plasma LDL-C concentrations associated with sterol/stanol 
consumption may be as large as 10% (26,27). This could lead to reductions in CVD if the 
effect is associated with a reduction in cardiovascular events similar to that induced by other 
drugs with similar lipid-lowering efficacy. As sterols/stanols reduce the intestinal absorption 
of cholesterol, their effect may be additive to that of statins which act by the reduction of 
hepatic cholesterol production. Importantly, a meta-analysis of 15 randomized controlled trial 
would appear to suggest that this is the case. It was found that a combination of statins and 
stanols/sterols lowered the levels of TC and LDL-C to a greater extent than with statins alone. 
HDL-C and triglyceride concentrations were not altered by the addition of sterols/stanols to 
statin therapy (28). Another meta-analysis demonstrated that the lipid-lowering efficacy of 
plant sterols/stanols was similar when the sterols were consumed as part of the diet and when 
they administered as a nutraceutical supplement (26), thus allowing for flexibility in the 
method of drug delivery.  
Some evidence exists regarding the effect of sterol consumption on cardiovascular outcomes. 
Observational data suggest that high intake of plant sterols might be associated with MI 
prevention in men (29). A recent, large observational study indicated that natural phytosterol 
intake was associated with TC and LDL-C reduction particularly in men. However, this 
beneficial effect on lipid profile did not result in a reduction in the risk of CVD (30). One 
explanation for the LDL-C reduction failing to translate into a reduction in CVD is that 
sterols/stanols may reduce the absorption of carotenoids and fat-soluble vitamins (31). Such 
an effect would be expected to be associated with a higher incidence of CVD (32), however 
further investigations are needed to determine whether this effect occurs in vivo.  
 
Polyphenols 
Several studies have indicated that grape polyphenols may influence plasma lipid 
concentrations. Consumption of grape juice has been associated with elevated HDL-C (33). A 
study of the effect of polyphenol-rich grape extract supplement (700 mg) on cardiovascular 
risk in healthy subjects and found that treatment was associated with a reduction in plasma TC 
and LDL-C concentrations (34). However, more extensive evidence in the form of a meta-
analysis of 9 randomized controlled trials (including 390 participants in total) did not find any 
effect of grape seed extract on LDL-C (35). While no effect was seen in this combined 
population, investigations of subpopulations and more sophisticated analysis of lipids has 
been carried out in other studies. One study found that plasma concentrations of large LDL-C 
and large LDL particles compared with placebo were decreased in obese subjects 
supplemented with grape powder for 3 weeks (36). However, the most atherogenic small LDL 
particles were not affected by treatment (37). 
Despite, great enthusiasm with respect to the potential health benefits of resveratrol 
supplementation, a recent meta-analysis did not demonstrate any effect of this compound on 
plasma levels of TC, LDL-C, triglycerides or glucose. A small reduction in HDL-C 
concentrations was observed (38). Larger, well-designed trials are necessary to confirm these 
outcomes. 
The results of studies investigating the effects of cocoa products on lipid profiles have been 
summarised in a meta-analysis of six randomized controlled trials (39). The results indicated 
that short-term cocoa consumption significantly lowered LDL-C by 5.87 mg/dL, marginally 
lowered TC by 5.82 mg/dL without any evidence of an effect upon HDL-C concentrations. 
The effects appeared to be dose-dependent and were observed in the subjects with elevated 
cardiovascular disease risks but not in healthy participants (39). A variety of cocoa derivatives 
exist and do not all necessarily have similar biological effects. Dark chocolate (which 
contains cocoa butter and cocoa powder) consumption was compared to white chocolate 
(which contains cocoa butter but not powder) consumption and no difference between the 
groups was observed in terms of triglyceride, LDL-C and HDL-C in diabetic patients with 
hypertension (40). Previous studies have failed to observe benefits of cocoa polyphenols on 
blood lipids in subjects with hypertension stage 1 (41), overweight (42) and in patients with 
heart failure (43). A recent meta-analysis of 19 randomized controlled trials of varying 
designs with a total of 1131 participants indicated that cocoa flavanols were associated with 
reductions in total triglycerides (-0.10 mmol/L) and increases in HDL-C (0.06 mmol/L) intake 
(44). Recently published results from the Flaviola Health Study revealed that twice-daily 
ingestion of 450 mg of cocoa flavanols for 1 month decreased TC by 0.20 mmol/l and LDL-C 
by 0.17 mmol/l whereas HDL-C increased by 0.10 mmol/l in a low risk, primary prevention 
population. The authors applied the Framingham Risk Score to their results and concluded 
that cocoa flavanols predicted a significant lowering of 10-year risk for CVD (45), however 
only well-designed (preferably randomized) studies can confirm whether this is the case. 
Tea polyphenols may also exert lipid-lowering effects. A meta-analysis of 14 randomized 
controlled trials including 1136 subjects in total found that the administration of green tea 
beverages or extracts resulted in significant reductions in serum TC and LDL-C 
concentrations, without altering HDL-C (46). Another meta-analysis of 20 randomized 
controlled trials appeared to confirm these results (47). In another study, both green and black 
tea and indicated that both reduced LDL-C whereas green tea also reduced TC (48). Similar 
properties of black tea were also confirmed by Zhao et al. (49). These observations highlight 
one of the difficulties of population research into nutraceuticals: Small differences in the 
preparation of foods, which are not always captured in food-frequency questionnaires, can 
result in important differences in the composition of the foods and therefore can result in 
varying biological effects. Black tea consumption was shown to be more effective in lowering 
LDL-C in subjects with hypercholesterolemia and other markers of elevated cardiovascular 
risk (49). A recent randomized, placebo-controlled trial demonstrated reduced LDL-C and 
non-HDL-C after long-term supplementation (12 months) with green tea extract in healthy 
postmenopausal women (50). 
Most studies to date have shown that plasma concentrations of HDL-C in humans are not 
affected by supplementation with grape products, cocoa and tea polyphenol. The exact 
mechanisms by green tea exert their LDL-C, lowering effects is not fully understood. 
Nevertheless, green tea is easily accessible, popular and safe and it may indirectly lead to 
lower morbidity and mortality rates due to CVD by improving hyperlipidemia outcomes. 
Armolipid Plus is a food supplement combining natural ingredients containing red yeast rice, 
policosanol, berberine, folic acid, astaxanthin and coenzyme Q10. It has been demonstrated 
that supplementation with this nutraceutical exert reduction of TC (-19.2%), LDL-C (-17.4%) 
and triglycerides (-16.3%) (51). A very recent meta-analysis of several randomized controlled 
trials revealed that this nutraceutical is safe, well tolerated and confirmed the beneficial 
effects upon lipid profile with reductions in plasma TC of 11-21% and reductions in LDL-C 
of 15-31% (52).  
 
Spirulina 
Spirulina supplementation has been associated with beneficial alterations to blood lipid 
profiles (53,54). Spirulina maxima, given orally (4.5 g/day, for 6 weeks), was associated with 
significant changes in TC and LDL-C concentrations (55). Furthermore, in a population of 
individuals with dyslipidemia, consumption of 1 g Spirulina per day for 12 weeks decreased 
mean levels of triglycerides, LDL-C, and TC without any apparent effect on plasma 
concentrations of HDL-C (56). A recent meta-analysis of seven randomized controlled trials 
with Spirulina appeared to confirm these findings (57). Further well-designed trials are 
required to clarify the mechanism of action of Spirulina supplementation in dyslipidemia and 
to determine its effects on cardiovascular outcomes. 
Table 1 summarizes the methodology and main findings from each study described in the 
paper.  
 
HYPERTENSION 
Hypertension is an important modifiable risk factor for CVD (58). It has been shown that 
lowering blood pressure reduces CV risk by 20-25% for myocardial infarction, 35-40% for 
stroke and about 50% for heart failure (59). The evidence relating to antihypertensive effects 
of selected nutraceuticals is outlined below.  
 
Sterols/stanols 
In contrast to the well-studied effects of sterols and stanols upon lipids, there is a relative 
paucity of evidence relating to their effects upon blood pressure. Studies have failed to 
demonstrate antihypertensive effects of sterols/stanols despite continuing treatment for a year 
or more (60,61). One recent study, which aimed to analyse the effect of plant stanol esters on 
arterial stiffness and endothelial function in adults also found no effect on measured blood 
pressure (62). Although the data are limited there appears to be no antihypertensive effects of 
these compounds in humans, neither is there any indication of adverse effects on blood 
pressure. 
 
Polyphenols 
It has been suggested that consumption of flavonoid-rich fruits and vegetables may lower 
blood pressure (63). Studies on the influence of polyphenols on blood pressure are very 
diverse and have included a great variety of polyphenol-containing foods, including: grapes, 
berries, cocoa product, tea and other. Some studies have demonstrated a significant beneficial 
effect of grape-derived polyphenols on blood pressure (64,65). On the other hand, there also 
numerous studies which did not identify such an association (66,67,68). The conflicting 
results probably result from the heterogeneity of study design, polyphenol source and 
population characteristics.  
A recently published randomized controlled trial indicated that grape seed extract 
significantly reduced systolic blood pressure by 5.6% and diastolic blood pressure by 4.7% 
after 6 weeks of supplementation in subject with mildly elevated blood pressure. Moreover, 
the blood pressure lowering effects appeared to be dependent on baseline blood pressure, with 
the greatest reduction observed in subjects with higher baseline blood pressure (69). 
The effects of resveratrol on blood pressure have also been studied. A meta-analysis of 6 
randomized controlled trials, (247 subjects), appeared to show a dose-response relationship 
only higher doses (≥150 mg day–1) of resveratrol significantly reduced systolic blood 
pressure while there were no significant effects on diastolic blood pressure (70). Another 
meta-analysis, which included data from 10 randomized controlled trials indicated that 
resveratrol supplementation did not affect systolic and diastolic blood pressure (38). 
Differences in the baseline blood pressure of participants in the study may account for some 
of these discrepancies. 
Cocoa flavanols are the most studied polyphenols in the clinical setting. A meta-analysis of 20 
randomized controlled trials involving healthy participants indicated that consumption of 
polyphenol-rich cocoa products was associated with a reduction in blood pressure (71). A 
meta-analysis of 42 randomized controlled trials indicated that chocolate or cocoa was 
associated with reduced diastolic blood pressure and mean arterial pressure (72). Very recent 
clinical studies also confirm that cocoa flavanols exert a beneficial impact on blood pressure 
in patients with type 2 diabetes and hypertension (40) and in elderly subjects (73). Moreover, 
a recent study has demonstrated similar findings after cocoa ingestion in healthy individuals 
(74). This was associated with a dose-dependent improvement in flow-mediated dilation, 
decreased endothelin-1 and pulse wave velocity. These findings warrant further investigation 
into the potential uses for cocoa in the prevention of CVD (74). 
Conversely, another study found no evidence of an effect of daily intake of dark chocolate (49 
g/day) on blood pressure or arterial stiffness in patients with mild hypertension (75). The 
Flaviola Health Study found that cocoa flavanol intake (450 mg) for 1 month decreased 
systolic and diastolic blood pressure by 4.4 mmHg and 3.9 mmHg, pulse wave velocity by 0.4 
m/s and led to improved endothelial function in a healthy, primary prevention population, 
suggesting potential benefits of cocoa in maintain cardiovascular health (45). 
Studies on tea polyphenols have also reported blood pressure lowering properties (48,76). A 
meta-analysis of 10 trials (834 participants) demonstrated that a statistically significant 
reduction in systolic blood pressure was associated with diastolic blood pressure with black or 
green tea consumption (77). Furthermore, a recent meta-analysis on the effects of green tea 
intake on risk of cardiovascular disease indicated that consumption of green tea is associated 
with reduced risk of myocardial infarction and stroke (78).  
Several clinical studies have demonstrated an antihypertensive effect of pomegranate juice. A 
recent meta-analysis, which included the results of eight randomized controlled trials 
investigating the effects of pomegranate juice on blood pressure indicated that consumption of 
this polyphenol-rich juice significantly reduced both systolic and diastolic blood pressure 
(79). In addition, lipid-lowering, antioxidant and anti-atherosclerotic actions of pomegranate 
juice have been reported, making it a very attractive candidate as a nutraceutical with the 
potential to improve cardiovascular health (80). 
The nutraceutical product, Armolipid Plus (containing red yeast rice, policosanol, berberine, 
folic acid, astaxanthin and coenzyme Q10) was found to be safe, well tolerated and effective 
in reducing mean 24-h systolic and 24-h pulse pressure in hypertensive and 
hypercholesterolemic subjects at low cardiovascular risk (51). 
 
Spirulina 
Some studies indicated that Spirulina maxima might exert an antihypertensive effect. Oral 
Spirulina supplementation resulted in systolic and diastolic blood pressure reduction in a 
small clinical trial (55). Conversely, no effect of Spirulina upon blood pressure was observed 
after consumption of 1 g Spirulina per day for 12 weeks in a Greek population (56). 
Administration of 2 g Hawaiian Spirulina for 3 months was associated with improved blood 
pressure and endothelial function in patients with hypertension. However, evidence relating to 
cardiovascular outcomes is lacking and further well-designed trials are required to clarify the 
clinical value of Spirulina supplementation in lowering blood pressure (81). 
Table 1 summarizes the methodology and main findings from each study described in the 
paper.  
DIABETES MELLITUS 
Diabetes mellitus is a well-established risk factor for cardiovascular disease. Diabetes mellitus 
type 2 is associated with high risk for developing cardiovascular complications (82). 
Moreover, patients with diabetes and hypertension have about twice the risk of cardiovascular 
events as nondiabetic patients with hypertension (83). It has been estimated that the global 
prevalence of diabetes mellitus will rise to 552 million by 2030 (84). Observational studies 
indicated that diet is one of the factors, which might prevent diabetes and its complications 
(85). The TOSCA observational study demonstrated that a diet characterized by a higher 
intake of total polyphenols was associated with a better cardiovascular risk factors profile and 
a lower grade of subclinical inflammation in population with diabetes mellitus type 2 (86).  
 
Polyphenols 
Relatively few studies have evaluated the effects of grape polyphenol on hyperglycemia. 
Guilford et al. (87) indicated that regular red wine consumption is associated with a 30% risk 
reduction for type 2 diabetes. Consumption of grape seed polyphenols and red wine grape 
pomace flour have been associated with significant reductions in blood glucose (88,89). 
Conversely another study found no effect of grape juice polyphenols in healthy individuals 
(90). 
A randomized controlled trial revealed that supplementation of resveratrol for 3 months 
significantly improved the mean hemoglobin A1c, in patients with type 2 diabetes mellitus 
(91). A recent meta-analysis of 11 randomized controlled trials found that resveratrol reduced 
fasting glucose, insulin, glycated hemoglobin, and insulin resistance in subjects with type 2 
diabetes, but not in those without diabetes (92). Conversely, a meta-analysis of 10 randomized 
controlled trials did not indicate a significant effect of resveratrol supplementation upon 
glucose level (38). The mechanism of action of resveratrol in the treatment of diabetes 
mellitus seems to be multifactorial; resveratrol may have antioxidant properties, increase 
AMPK activation, and increase internalization of glucose through modulating glucose 
transporter expression (93,94,95). 
Results from studies evaluating influence of cocoa and tea polyphenols on glycemic markers 
are inconclusive. A meta-analysis of 42 randomized controlled trials indicated that chocolate 
or cocoa reduced fasting insulin concentrations, insulin after glucose challenge and improved 
insulin resistance. However, no effect upon fasting glucose or HbA1c was observed (72). 
Consumption of chocolate high in polyphenols was not associated with differences in fasting 
insulin in patients with diabetes mellitus type 2 and hypertension (40). 
Another study found an independent inverse relationship between daily chocolate intake and 
concentrations of insulin, homeostatic model assessment of insulin resistance (HOMA-IR) 
and liver enzymes. Results of that study suggest that chocolate intake result in beneficial 
changes in liver enzymes and protect against insulin resistance (96). The results of a 
randomized controlled trial also support a role for cocoa flavanol intake in improving insulin 
resistance (44). The current data is insufficient to recommend chocolate and cocoa for 
glycemic control. 
A meta-analysis of 17 trials comprising a total of 1133 subjects revealed that green tea 
consumption was associated with significantly reduced fasting glucose and hemoglobin A1c 
(97). Furthermore, a meta-analysis of has also indicated changes in fasting glucose but 
glycated hemoglobin similar as fasting blood insulin and HOMA-IR did not change after 
green tea catechins administration (98). In a meta-analysis of 10 trials, which evaluated effect 
of green tea on populations at risk of diabetes mellitus type 2, green tea was not associated 
with reduced levels of fasting plasma glucose, fasting serum insulin, 2-h plasma glucose in 
the oral glucose tolerance test, hemoglobin A1c (HbA1c) and HOMA-IR (99). 
Recent meta-analysis of 10 trials including 608 subjects which aimed to indicate the effect of 
green tea in patients with diabetes mellitus type 2 found that tea could alleviate the decrease 
of fasting blood insulin and reduced waist circumference only when the intervention was 
extended for longer than 8-weeks. No effects of tea on HOMA-IR, fasting blood glucose, 
LDL-C, HDL-C, body mass index, systolic blood pressure, diastolic blood pressure, 
triglycerides and fasting cholesterol were observed (100). These mixed results mean that it is 
unclear whether green tea has anti-diabetic effects. 
Polyphenols might influence glucose homeostasis by several mechanisms, by inhibiting 
carbohydrate digestion and glucose absorption in the intestine, protecting pancreatic β-cells, 
reducing glucose release from liver and activating insulin receptors and glucose uptake in 
insulin-sensitive tissues (101). 
 
Spirulina 
Spirulina might be beneficial in controlling blood glucose level in subject with diabetes 
mellitus type 2. Supplementation of 2 g/day for 2 months resulted in reduced fasting blood 
glucose, postprandial blood glucose levels and HbA1c (53). Conversely oral supplementation 
of Spirulina in a separate trial (4.5 g/day, for 6 weeks) did not result in changes in the markers 
of glucose metabolism (55). Further trials are required to clarify the clinical value of Spirulina 
supplementation in treatment of diabetes. 
Table 1 summarizes the methodology and main findings from each study described in the 
paper.  
 
CONCLUSIONS 
Dyslipidemia, hypertension and diabetes are major modifiable risk factors for CVD. Current 
medical treatments for the management of diabetes and dyslipidemia in some especially high 
risk patients are insufficient and current evidence suggests that the application of 
nutraceuticals may have the potential to increase the effectiveness of therapy (as well as to 
reduce the residual risk). Many of the nutraceuticals investigated for the prevention and 
treatment of CVD are well tolerated in patients. However, there is often insufficient data 
available with respect to long-term safety and effectiveness against clinical outcomes such as 
myocardial infarction and mortality. Further clinical research should be conducted to identify 
nutraceuticals with the best clinical and cost-effectiveness in the prevention and treatment of 
cardiovascular disease (102-105). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. The main findings of the studies on the application of selected nutraceuticals in dyslipidemia 
and/or diabetes and/or hypertension.  
 
Refe
renc
e 
Study design Subjects 
characteristic 
Intervention Results 
STEROLS/STANOLS 
(26) Meta-analysis 
of 9 RCTs 
263 
participants 
Plant sterols/stanols 
dose range: 1.0- 3.0 
g/day; duration range: 
4-6 weeks 
LDL-C reduction by 12 mg/dL 
 
(27) Meta-analysis 
of 124 RCTs 
624 
participants 
Phytosterols dose 
range: 0.2 - 9.0 g/d 
LDL-C reduction by 6-12% ( 
0.6-3.3 g/d); dose–response 
relationships 
(28) Meta-analysis 
of 15 RCTs   
500 patients 
treated with 
statins  
Plant sterols/stanols 
dose range: 1.8 – 6 
g/d; duration range: 4 - 
85 weeks 
TC and LDL-C reduction by  
0.30 mmol/L;  
no changes in HDL-C and TG 
(29) Nested case-
referent study 
1005 
individuals 
(219 women, 
786 men) 
Plant sterols, 128 – 
341 g/d 
Increasing sterol intake from 
150 to 340 mg/d reduces the risk 
of a first MI by 29% in men 
(30) Observational 
study 
35 597 Dutch 
men and 
women 
Phytosterols, dose 
range: 231.3 – 366.0 
mg/d; follow-up 12.2 
years  
TC (-0.06 mmol/l), LDL-C (-
0.07 mmol/l) reduction;  
no effect on CVD risk  
(60) Randomized, 
double-blind, 
parallel 
282 mildly 
to 
moderately 
hypercholest
erolemic 
subjects  
Stanols or sterols, 2 
g/day for 1 year 
Glucose increased by 1–3%; 
No effect on BP, CRP 
(61) Case–control 
study 
100 healthy 
subjects 
Plant stanol ester 
margarine for a period 
of 2 years or longer 
No effect on lipoproteins, BP, 
FMD and intima-media 
thickness 
(62) Randomized, 
controlled, 
double-blind, 
parallel trial 
92 
asymptomati
c subjects 
Plant stanols, 3.0 g/d 
for 6 months 
TC, LDL-C, non-HDL-C 
declined 
by 6.6, 10.2, and 10.6%, reduced 
arterial stiffness in small 
arteries; 
No effect on BP, glucose, TG 
GRAPE POLYPHENOLS 
(33) Single arm 
intervention 
26 healthy 
meals 
Red grape juice 150 
ml twice per day for 4 
weeks 
HDL-C, ApoB increase; Hcy 
level reduction;  
no effect on ApoAI level  
(34) Randomized, 
double-blind, 
placebo-
controlled 
clinical trial 
60 healthy 
subjects 
Grape extract 
Eminol®, 700 mg/ day 
for 8 weeks 
TC, LDL-C reduction 
(35) Meta-analysis 
of 9 RCT 
390 
participants 
Grape seed extract 
dose range:150 – 2000 
mg/d; duration range: 
2 –  24 weeks 
SBP (-1.54 mm Hg), heart rate 
(-1.42 bpm) reduction; 
no effect on DBP, lipid levels, 
CRP 
(36) Randomized, 
double-blind, 
placebo-
controlled, 
cross-over  
24 obese 
subjects 
Grape powder, 46 g 
twice per day for 3 
weeks 
Reduction of large LDL-C and 
large LDL particles 
(64) Randomized 
double blind 
placebo-
controlled 
crossover 
24 males 
with 
metabolic 
syndrome 
Grape polyphenol 
powder, 267 mg/day 
for 30 days  
SBP reduction; 
no change in DPB, HDL-C, 
fasting plasma glucose 
(65) Randomized 
double-
blinded, 
placebo 
controlled, 
incomplete-
crossover  
60 males 
mildly 
hypertensive 
(a) Grape-red wine 
extract or (b) grape 
extract, 800 mg/day 
for 4 weeks 
(a)SBP, DBP reduction 
(a) and (b): 
no changes in TC, LDL-C, 
HDL-C, TG and  vascular 
function parameters 
(66) Randomized, 
double-blind, 
placebo-
controlled, 
parallel  
50 pre- and 
mild-
hypertension 
subjects 
Red grape cell powder, 
200 mg or 400 mg for 
12 weeks 
DBP reduction only in 200 mg 
group;  
No effect on SBP, FMD 
 
 
(67) Randomized, 
double-blind, 
placebo-
controlled trial 
69 
hypertensive 
individuals 
Grape-seed 
polyphenols 1000 
mg/d, vitamin C 500 
mg/d 
No effect on SBP, DBP and 
pulse pressure variation 
(68) Controlled 
intervention 
28 healthy 
young adults 
Grape and 
pomegranate juice, 
200 mL/day for 8-
week 
No effect on lipid profile, 
inflammation, BP or glycaemia  
(69) Randomized, 
double-
blinded, two-
arm, parallel, 
placebo-
controlled trial 
36 pre-
hypertension 
subjects 
Grape seed; 300 mg/d 
twice daily for 6weeks 
Reduced SBP by 5.6% and DBP 
by 4.7%; effects were more 
marked in subjects with higher 
baseline BP; 
no effect on fasting plasma 
lipids, glucose, oxidised LDL, 
FMD 
(89) Randomized, 
controlled, 
prospective,  
parallel-group 
trial 
38 patients 
with 
metabolic 
syndrome  
Red wine grape 
pomace flour, 20g/day 
for 16 weeks 
Improvement in blood pressure, 
glycaemia and postprandial 
insulin 
(90) Randomized, 
controlled,  
crossover, 
intervention 
trial 
24 healthy 
individuals 
Tropical grape juice 
(Vitis labrusca L.), 400 
mL for 14 days 
Increase in antioxidant 
biomarkers; 
No effect on glucose and uric 
acid level 
(91) Randomized, 
prospective, 
open-label, 
controlled trial 
 62 patients 
with T2DM  
Resveratrol, 250 mg/ 
d for 3 months 
Improvement in HbA1c, SBP, 
TC, and total protein levels; 
No changes in body weight, 
HDL-C, LDL-C 
(92) Meta-analysis 
of 11 RCTs 
388 subjects 
with and 
without 
Resveratrol, dose 
range: 10 – 1500 
mg/d; 
Reduction in fasting glucose, 
insulin, HbA1c, and insulin 
resistance in T2DM; 
T2DM duration range: 2 –  24 
weeks 
No effect on glycemic measures 
of nondiabetic participants  
(38) Meta-analysis  
of 10 RCTs 
575 
participants 
Resveratrol dose 
range: 8 – 1500 
mg/day; duration 
range: 4 - 26 weeks 
Reduction in HDL-C; 
no effect on TC, LDL-C, TG, 
glucose, SBP, DBP, CRP 
(70) Meta-analysis 
of 6 RCTs 
247 subjects Resveratrol, dose 
range: 16 mg – 1 
g/day); duration range: 
12 – 48 weeks 
At dose ≥150 mg day–1 SPB 
reduction no effect on DBP 
COCOA POLYPHENOLS 
(39) Meta-analysis 
of 8 RCTs 
215 
participants 
Cocoa products dose 
range: 88 – 963 
mg/day; duration 
range: 2 –  18 weeks 
LDL-C and TC reduction by 
5.87 mg/dL, changes depend on 
the dose of cocoa and the 
healthy status of participants;  
no effect on HDL-C  
(40) Randomized, 
placebo-
controlled, 
double-blind 
study 
T2DM 
patients with 
hypertension 
Dark chocolate, 25 
g/day for 8 weeks 
Increase in ApoA1; 
HbA1c, Apo B, SBP, DBP, FBS 
reduction;  
No effect on TG, LDL-C, HDL-
C, BP, insulin resistance or 
glycemic control 
(41) Intervention 
clinical trial 
22 subjects 
with 
hypertension 
stage 1 
Chocolate 50 g, 70% 
cocoa/day (2135 mg 
polyphenols) for 4 
weeks 
No effect on glucose 
metabolism, lipid profile, 
biomarkers of inflammation, 
adhesion molecules, oxidized 
LDL, and blood pressure 
(42) Randomized, 
placebo-
controlled, 
cross-over 
study 
30 
overweight 
adults 
Cocoa/chocolate,  
37 g/d dark chocolate  
and a sugar-free cocoa 
beverage (dose of 
cocoa = 22 g/d, total 
flavanols = 814 mg/d) 
for 4 weeks 
Increase in resting BP by 4 
mmHg, reduction in arterial 
stiffness in women; 
No effect on fasting BP, 
glucose, blood lipids 
(43) Randomized, 
double-blind, 
placebo-
controlled trial 
22 patients 
with stable 
CHF (NYHA 
≥ II)  
 
Flavanol-rich 
chocolate 40g/d for 4 
weeks 
Improvement of endothelial 
function; 
No effect on SBP, DBP, HR, 
glucose, HbA1c, TC, LDL-C, 
HDL-C, TG 
(44) Meta-analysis 
of 19 RCTs  
1131 
participants 
Cocoa flavanols, dose: 
166 –  2110 mg/d; 
duration: 2 – 52 weeks 
HDL-C increase, TG reduction, 
improvement in insulin 
resistance 
(45) Randomized, 
controlled, 
double-
masked trial 
low risk, 
healthy, 
middle-aged 
individuals 
without 
history of 
CVD 
Cocoa flavanols, 450 
mg twice a day for 4 
weeks 
Reduction of SBP by 4.4 
mmHg, DPB by 3.9 mmHg, 
PWV by 0.4 m/s, TC by 0.20 
mmol/l , LDL-C by 0.17 mmol/l 
reduction, HDL-C increase by 
0.10 mmol/l; 
(71) Meta-analysis 
of 20 RCTs 
856 mainly 
healthy 
participants  
Flavanol-rich cocoa 
products, 30 –  1080 
mg of flavanols per 
day, duration range: 2 
–  18 weeks 
BP reduction by 2-3 mm Hg 
(72) Meta-analysis 
of 42 RCTs 
1297 
participants 
Chocolate, cocoa, or 
flavan-3-ols 
DBP, mean arterial pressure, 
fasting insulin and insulin after 
glucose challenge reduction; 
improvement in HOMA-IR, 
FMD  
(73) Randomized, 
double-blind, 
controlled, 
parallel-arm 
90 elderly 
subjects 
Cocoa flavanols, 993 
mg, 520 mg or 48 mg 
for 8 weeks 
SBP, DBP, glucose, insulin, 
HOMA-IR, reduction and 
Increase in HDL-C only among 
subjects taking 993 mg and 520 
mg 
(74) Randomized, 
double-blind, 
controlled, 
cross-over 
design, 
20 healthy 
individuals 
Cocoa flavonoids 
exert, 10 g cocoa (0, 
80, 200, 
500 and 800 mg cocoa 
flavonoids/day) in 5 
periods lasting 1 week 
each 
DPB, SBP reduction; 
FMD improvement, endothelin-
1 and PWV reduction by 
ameliorating blood pressure 
(75) Randomized, 
controlled, 
cross-over trial 
22 mild 
hypertension 
Dark chocolate, 49 
g/day for 8 weeks 
No effect on BP and arterial 
stiffness 
(96) Cross-
sectional 
observation 
study 
1153 
individuals 
Chocolate Higher chocolate consumption 
was associated with lower 
HOMA-IR, serum insulin levels, 
γ-GT  and ALT 
GREEN/BLACK TEA POLYPHENOLS 
(46) Meta-analysis 
of 14 RCTs   
1136 
subjects 
Green tea beverages or 
extracts, dose range 
respectively: 340 – 
900 mL, 250 mg – 9 g 
per day; duration 
range: 2 - 12 weeks 
Reduction of TC by 7.20 mg/dL, 
LDL-C by 2.19 mg/dL;  
no effect on HDL-C 
(47) Meta-analysis 
of 20 RTCs 
1415 
participants 
Green tea catechins 
dose range: 145 - 
3,000 mg/day; 
duration range: 3 - 24 
weeks 
TC (-5.46 mg/dL), LDL-C (-
5.30 mg/dL) reduction; no effect 
on HDL-C, TG 
(48) Meta-analysis 
of 11 RCTs 
821 
participants 
Green and black tea, 
duration range: 12 - 48 
weeks 
Green tea: TC (-0.62 mmol/L) , 
LDL-C (-0.64 mmol/L) , SBP -
3.18 mmHg), DBP (-3.42 
mmHg) reduction; 
Black tea: LDL-C (-0.43 
mmol/L), SBP (-1.85 mmHg), 
DBP (-1.27 mmHg) reduction 
(49) Meta-analysis 
of 10 RCTs 
411 
participants 
Black tea beverage or 
extract, duration range: 
4 – 24 weeks 
LDL-C (-4.64 mg/dL) reduction; 
black tea more effective in 
lowering LDL-C in the subject 
with higher CV risk such as 
HCh;  
no effect on TC and HDL-C 
(50) Randomized, 
double-blind, 
placebo-
controlled, 
parallel-arm 
936 healthy 
postmenopau
sal women 
Green tea extract, 
1315 mg catechins per 
day, duration: 12 
months 
TC, LDL-C and non-HDL-C 
reduction; 
No effect on HDL-C 
trial 
(76) Meta-analysis 
of 13 RCTs 
947 
participants 
Green tea extract or 
beverages, catechins 
100 – 1500 mg, 
Duration range: 3 – 16 
weeks 
SBP (-2.08 mm Hg), DBP (-1.71 
mm Hg), TC (-0.15 mmol/L), 
LDL-C (-0.16 mmol/L) 
reduction 
(77) Meta-analysis 
of 10 trials 
834 
participants 
Green tea extract or 
beverages, 250 – 583 
mg/day, duration 
range: 8 – 14 weeks 
SBP (MD -2.36mmHg), and 
DBP (MD -1.77mmHg) 
reduction 
(78) Meta-analysis 
of 9 RCTs 
259,267 
individuals 
Green tea beverages, 
follow-up: 9 week – 
13 years 
1–3 cups of green tea per day 
reduced risk of MI and stroke 
compared to ˂1 cup/day, ≥4 
cups/day reduced risk of MI 
compared to ˂ 1 cup/day; ≥10 
cups/day of green tea 
lowered LDL compared to the ˂ 
3 cups/day group 
(97) Meta-analysis 
of 17 RCTs 
1133 
subjects 
green tea, catechin 
content range:208 to 
1207 mg/d; 
duration range: 8 – 24 
weeks  
Fasting glucose (-0.09 mmol/L) 
and HbA1c (-0.30%) reduction; 
no effect on fasting insulin and 
HOMA-IR 
(98) Meta-analysis 
of 22 RCTs 
1584 
subjects 
Green tea catechins, 
dose range: 456 – 
1206.9 mg/d; 
duration range: 3 – 12 
weeks 
Fasting blood glucose (-1.48 
mg/dL) reduction;  
no changes in FBI, HbA1c or 
HOMA-IR 
(99) Meta-analysis 
of 7 RCTs 
510 subjects 
at risk of 
T2DM 
Green tea (900 – 1200 
mL) or green tea 
extract (558 – 1500 
mg), duration range: 4 
– 24 weeks 
No changes in fasting plasma 
glucose, fasting serum insulin, 
2-h plasma glucose in the oral 
glucose tolerance test, HbA1c 
and HOMA-IR 
(100
) 
Meta-analysis 
of 10 trials   
608 subjects Green tea (150 – 1500 
mL) or green tea 
extract, catechins (240 
– 750 mg), duration 
range: 4 – 16 weeks 
Alleviate the decrease of fasting 
blood insulin and reduced waist 
circumference only in 
intervention ˃8-week;  no effect 
on HOMA-IR, fasting blood 
glucose, LDL-C, HDL-C, BMI, 
SBP, DBP, TG and fasting 
cholesterol  
ARMOLIPID PLUS 
(51) Non-
randomized, 
controlled, 
study 
66 patients 
with HT and 
HCh with 
low CV risk 
Armolipid Plus, 1 
tablet for 6 months 
TC (-19.2%), LDL-C (-17.4%), 
TG (-16.3%), 24-h SBP, DBP 
reduction; no effect on HDL-C 
(52) Meta-analysis 
of 13 RCTs 
mostly 
patients with 
mild to 
moderate 
dyslipidemia 
Armolipid Plus for 6-
48 weeks 
TC (11-21%) LDL-C (15-31%) 
reduction 
SPIRULINA 
(53) Randomized 
placebo-
25 T2DM 
subjects 
Spirulina, 2 g/day for 2 
months 
TC, LDL-C reduction, HDL-C 
increase; fasting blood glucose, 
controlled, 
parallel-group 
trial 
postprandial blood glucose 
levels,  HbA(1c) reduction; 
improvement in long-term 
glucose regulation 
(54) Randomized 
placebo-
controlled, 
parallel-group 
trial 
37 T2DM 
subjects 
Spirulina, 8 g/day for 
12 weeks 
TG reduction 
(55) Open-label, 
non-
randomized,  
36 healthy 
subjects 
Spirulina maxima, 4.5 
g/day for 6 weeks 
TC, LDL-C, SBP, DPB 
reduction; no change in glucose 
(56) Open-label, 
non-
randomized,  
52 
dyslipidemic 
subjects 
Spirulina, 1 g per day 
for 12 weeks 
TG (16.3%), LDL-C (10.1%), 
TC (8.9%), non-HDL-C 
(10.8%), ratio of TC HDL-C 
11.5% reduction;  
no effect on HDL-C, BP 
 (57) Meta-analysis 
of 7 RCTs 
522 
participants 
Spirulina, dose range: 
1 – 10 g/day;  
duration range: 8 - 48 
weeks 
TC, LDL-C,  TG reduction; 
elevating those of HDL-C (6.06 
mg/dL) 
(81) Randomized, 
double-blind, 
placebo-
controlled trial 
40 
hypertensive 
patients with 
lacking 
evidence of 
CVD 
Hawaiian Spirulina, 2 
g/day for 3 months 
Reduction in BMI, weight, SBP 
and stiffness index 
 
*Abbreviations: PWV – pulse wave velocity, MI –- myocardial infarction, ApoAI – apolipoprotein AI, ApoB –
apolipoprotein B, Hcy – homocysteine, FBS – fasting blood sugar, HbA1c – hemoglobin A1c, HOMA-IR – 
homeostasis model assessment–insulin resistance, CHF – congestive heart failure, HT – hypertension, HCh –  
hypercholesterolemia, FBG – fasting blood glucose, FBI – fasting blood insulin. 
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